The primary objective of the M22-A3 guideline is to define the responsibilities of both the manufacturer and the end-user laboratory regarding the quality control (QC) of microbiological media. Historically, laboratories were often required to perform extensive "in-house" testing on every batch of commercially prepared media to ensure sterility and growth support. However, M22-A3 identifies specific media with a high history of stability and consistent performance, classifying them as "exempt" from routine user QC testing, provided the manufacturer is compliant with stringent quality standards. This classification allows laboratories to trust the manufacturer’s Certificate of Analysis (CoA) for low-risk media, such as Blood Agar or MacConkey Agar, thereby reducing the consumption of reagents, personnel time, and financial resources.
The Clinical and Laboratory Standards Institute (CLSI) document M22-A3, "Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard — Third Edition," is a cornerstone reference for clinical microbiology laboratories performing disk diffusion antimicrobial susceptibility testing (AST). This essay explains the document’s purpose and key content, its impact on laboratory practice and patient care, and how clinicians and laboratorians can responsibly access and use the standard (including locating the PDF through legitimate channels). clsi m22a3 pdf link
Because CLSI standards are copyrighted materials, they are typically not available for free download as a full PDF. You can obtain official copies through the following platforms: The primary objective of the M22-A3 guideline is